Page last updated: 2024-11-12

papyriflavonol a

Description Research Excerpts Clinical Trials Roles Classes Pathways Study Profile Bioassays Related Drugs Related Conditions Protein Interactions Research Growth Market Indicators

Description

papyriflavonol A: isolated from Broussonetia papyrifera; structure in first source [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]

papyriflavonol A : A pentahydroxyflavone that is flavone substituted with hydroxy groups at positions 3, 5, 7, 3' and 4' and prenyl groups at positions 6 and 5'. Isolated from Broussonetia papyrifera, it exhibits inhibitory activity against phospholipase A2 and tyrosinase. [Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

FloraRankFlora DefinitionFamilyFamily Definition
BroussonetiagenusA plant genus of the family MORACEAE. Members contain PYRROLIDINES.[MeSH]MoraceaeThe mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH]
Broussonetia papyriferaspecies[no description available]MoraceaeThe mulberry plant family of the order Urticales, subclass Hamamelidae, class Magnoliopsida. They have milky latex and small, petalless male or female flowers.[MeSH]

Cross-References

ID SourceID
PubMed CID10343070
CHEMBL ID457303
CHEBI ID66727
MeSH IDM0394811

Synonyms (16)

Synonym
CHEMBL457303
chebi:66727 ,
papyriflavonol a
LMPK12112289
broussonol e
3,5,7,3',4'-pentahydroxy-6,5'-di-(3-methyl-2-butenyl)flavone
2-[3,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl]-3,5,7-trihydroxy-6-(3-methylbut-2-en-1-yl)-4h-chromen-4-one
5,7,3',4'-tetrahydroxy-6,5'-di-(gamma,gamma-dimethylallyl)-flavonol
bdbm50486898
2-[3,4-dihydroxy-5-(3-methylbut-2-enyl)phenyl]-3,5,7-trihydroxy-6-(3-methylbut-2-enyl)chromen-4-one
5,7,3',4'-tetrahydroxy-6,5'-di-(gamma,gammadimethylallyl)-flavonol
Q27135348
363134-28-5
HY-N10904
CS-0637509
2-(3,4-dihydroxy-5-(3-methylbut-2-en-1-yl)phenyl)-3,5,7-trihydroxy-6-(3-methylbut-2-en-1-yl)-4h-chromen-4-one

Research Excerpts

Actions

ExcerptReferenceRelevance
"Papyriflavonol A was found to inhibit human group IIA and V sPLA(2)s potently and irreversibly in a dose-dependent manner, with respective IC(50) values of 3.9 and 4.5 microM."( Papyriflavonol A from Broussonetia papyrifera inhibits the passive cutaneous anaphylaxis reaction and has a secretory phospholipase A2-inhibitory activity.
Chang, HW; Jung, H; Kang, SS; Kim, HP; Kudo, I; Kwak, WJ; Kwon, DY; Lee, E; Lin, CX; Moon, TC; Murakami, M; Rhyn, HG; Son, KH, 2003
)
2.48
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Roles (3)

RoleDescription
metaboliteAny intermediate or product resulting from metabolism. The term 'metabolite' subsumes the classes commonly known as primary and secondary metabolites.
EC 3.1.1.4 (phospholipase A2) inhibitorAn EC 3.1.1.* (carboxylic ester hydrolase) inhibitor that interferes with the action of phospholipase A2 (EC 3.1.1.4).
EC 1.14.18.1 (tyrosinase) inhibitorAny EC 1.14.18.* (oxidoreductase acting on paired donors, miscellaneous compound as one donor, incorporating 1 atom of oxygen) inhibitor that interferes with the action of tyrosinase (monophenol monooxygenase), EC 1.14.18.1, an enzyme that catalyses the oxidation of phenols (such as tyrosine) and is widespread in plants and animals.
[role information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Drug Classes (3)

ClassDescription
flavonolsAny hydroxyflavone in which is the ring hydrogen at position 3 of the heterocyclic ring is replaced by a hydroxy group.
pentahydroxyflavoneA hydroxyflavone substituted by five hydroxy groups.
3'-hydroxyflavonoidAny hydroxyflavone with a hydroxy substituent at position 3'.
[compound class information is derived from Chemical Entities of Biological Interest (ChEBI), Hastings J, Owen G, Dekker A, Ennis M, Kale N, Muthukrishnan V, Turner S, Swainston N, Mendes P, Steinbeck C. (2016). ChEBI in 2016: Improved services and an expanding collection of metabolites. Nucleic Acids Res]

Protein Targets (2)

Inhibition Measurements

ProteinTaxonomyMeasurementAverageMin (ref.)Avg (ref.)Max (ref.)Bioassay(s)
Maltase-glucoamylase, intestinalHomo sapiens (human)Ki2.30000.17001.86737.3000AID1688680
Tissue alpha-L-fucosidaseBos taurus (cattle)IC50 (µMol)89.00000.00500.05750.1100AID1688689
[prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023]

Biological Processes (4)

Processvia Protein(s)Taxonomy
maltose catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
starch catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
dextrin catabolic processMaltase-glucoamylase, intestinalHomo sapiens (human)
glycolipid catabolic processTissue alpha-L-fucosidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Molecular Functions (8)

Processvia Protein(s)Taxonomy
catalytic activityMaltase-glucoamylase, intestinalHomo sapiens (human)
glucan 1,4-alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-1,4-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
protein bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
amylase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
carbohydrate bindingMaltase-glucoamylase, intestinalHomo sapiens (human)
maltose alpha-glucosidase activityMaltase-glucoamylase, intestinalHomo sapiens (human)
alpha-L-fucosidase activityTissue alpha-L-fucosidaseBos taurus (cattle)
[Information is prepared from geneontology information from the June-17-2024 release]

Ceullar Components (5)

Processvia Protein(s)Taxonomy
plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
apical plasma membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
extracellular exosomeMaltase-glucoamylase, intestinalHomo sapiens (human)
tertiary granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
ficolin-1-rich granule membraneMaltase-glucoamylase, intestinalHomo sapiens (human)
[Information is prepared from geneontology information from the June-17-2024 release]

Bioassays (9)

Assay IDTitleYearJournalArticle
AID357912Cytotoxicity against human KB cells after 5 days by MTT assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Five new diprenylated flavonols from the leaves of Broussonetia kazinoki.
AID1688689Inhibition of bovine kidney alpha-fucosidase using PNPG as substrate incubated for 10 mins by spectrophotometric method2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID1688680Mixed type inhibition of alpha-glucosidase (unknown origin) using p-nitrophenyl-alpha-D glucopyranoside as substrate incubated for 30 mins by Lineweaver-Burk plot analysis2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID357911Cytotoxicity against human HCT8 cells after 5 days by MTT assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Five new diprenylated flavonols from the leaves of Broussonetia kazinoki.
AID1688692Inhibition of jack bean alpha-mannosidase at 1 mM using PNPG as substrate incubated for 10 mins by spectrophotometric method2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID1688687Inhibition of Saccharomyces cerevisiae alpha-glucosidase using PNPG as substrate incubated for 10 mins by spectrophotometric method2020European journal of medicinal chemistry, Feb-15, Volume: 188Discovery of novel pyrido-pyrrolidine hybrid compounds as alpha-glucosidase inhibitors and alternative agent for control of type 1 diabetes.
AID1717786Inhibition of SARS-CoV His-tagged papain-like protease expressed in Escherichia coli BL21 (DE3) CodonPlus-RIL cells using Arg-Leu-Arg-Gly-Gly-AMC as substrate by fluorescence method2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID1717787Non-competitive inhibition of SARS-CoV His-tagged papain-like protease expressed in Escherichia coli BL21 (DE3) CodonPlus-RIL cells using Arg-Leu-Arg-Gly-Gly-AMC as substrate by Lineweaver-Burk plot analysis2020Journal of medicinal chemistry, 11-25, Volume: 63, Issue:22
Chinese Therapeutic Strategy for Fighting COVID-19 and Potential Small-Molecule Inhibitors against Severe Acute Respiratory Syndrome Coronavirus 2 (SARS-CoV-2).
AID357910Cytotoxicity against human A549 cells after 5 days by MTT assay2001Journal of natural products, Sep, Volume: 64, Issue:9
Five new diprenylated flavonols from the leaves of Broussonetia kazinoki.
[information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023]

Research

Studies (6)

TimeframeStudies, This Drug (%)All Drugs %
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's3 (50.00)29.6817
2010's1 (16.67)24.3611
2020's2 (33.33)2.80
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]

Market Indicators

Research Demand Index: 12.43

According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.

MetricThis Compound (vs All)
Research Demand Index12.43 (24.57)
Research Supply Index1.95 (2.92)
Research Growth Index4.37 (4.65)
Search Engine Demand Index0.00 (26.88)
Search Engine Supply Index0.00 (0.95)

This Compound (12.43)

All Compounds (24.57)

Study Types

Publication TypeThis drug (%)All Drugs (%)
Trials0 (0.00%)5.53%
Reviews1 (16.67%)6.00%
Case Studies0 (0.00%)4.05%
Observational0 (0.00%)0.25%
Other5 (83.33%)84.16%
[information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023]